|Day Low/High||80.77 / 84.40|
|52 Wk Low/High||64.18 / 86.72|
Despite some concerns, we expect to see strong earnings for the company moving forward as its new products continue to pay off.
Investors digest earnings from Alphabet Inc and Eli Lilly & Co.
U.S. stock futures turn higher on Tuesday following earnings from Alphabet.
Europe looks to rebound into earnings season
Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
Wall Street's first glimpse at the second quarter.
There are five over-tenured directors and four directors with whom CEO Ginni Rometty works with outside of the company, according to BoardEx.
Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
We're selling our shares in Walgreens as our bullish thesis has lost its luster.
We're adding Nvidia, removing TMO and Six Flags, plus 2 updates.
The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.
The FDA has given priority review designation for abemaciclib.